Author:
Sandström M.,Lindman H.,Nygren P.,Johansson M.,Bergh J.,Karlsson M.O.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference48 articles.
1. Beal S, Sheiner L (1999) NONMEM users guides. University of California, San Fransicso, CA
2. Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson NO, Malmstrom P, Kellokumpu-Lehtinen P, Anker G, Bennmarker H, Wilking N (1998) Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. Ann Oncol 9:403
3. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384
4. Cockroft D, Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
5. De Bruijn EA, Driessen OM, Hermans J (1991) The CMF-regimen. Toxicity patterns following stepwise combinations of cyclophosphamide, methotrexate and fluorouracil. Int J Cancer 48:67
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献